A trial of BA1301 for advanced solid tumors
Part of Cancer clinical trials.
This trial tests a new drug, BA1301, in people with advanced solid tumors that have not responded to standard treatments. The study aims to find a safe dose and see if BA1301 can help shrink or control the cancer.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must be between 18 and 75 years old.
- You must have an advanced solid tumor that cannot be surgically removed and has not responded to standard treatments, or you cannot have those treatments.
- You must be willing to provide a tumor sample (from a past biopsy or a new one) for testing a marker called CLDN18.2.
- You must be able to care for yourself (ECOG score 0 or 1) and have a life expectancy of at least 3 months.
- You must not have had certain cancer treatments (chemotherapy, radiation, targeted therapy, etc.) or major surgery within the last 28 days.
- You must not have active hepatitis B, hepatitis C, syphilis, or HIV.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a new drug, BA1302, for people with advanced solid tumors that have stopped responding to standard treatments. The study aims to see if BA1302 is safe and effective.
This trial is testing two new drugs (DB-1311 with BNT327 or DB-1305) in people with certain advanced or metastatic solid tumors that have not responded to prior treatments. It aims to see if the combination shrinks tumors or slows cancer growth.
This study tests a new drug called BI 3822971 for people with advanced cancer that has not responded to standard treatments. The goal is to find the best dose that is safe and well-tolerated.
This trial tests a new drug called BL-B16D1 for people with advanced solid tumors that haven't responded to other treatments. The goal is to see if this drug is safe and how well it works.
This Phase 1 study tests BA1202 in people with advanced solid cancers to find safe dosing and how the treatment may work. You may qualify if your cancer has progressed or you cannot use standard treatment, and—depending on the group—your tumor shows a specific marker called CEACAM5.
This trial tests a new drug called BL-B16D1 for people with advanced breast cancer or other solid tumors that have not responded to standard treatments. The goal is to see if the drug is safe and how well it works.
Hear when a new Advanced Solid Tumours trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.